author-photo

Taofeek K. Owonikoko

Emory University

457

Papers

12775

Citations

Citation Trend

Filter By

Papers (311) Sort By

Journal Conference Others

A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer

2021 bioRxiv
Show All
- Source
- Cite
- Save
Citations (0)
Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.

2021 Theranostics
Show All
- Source
- Cite
- Save
Citations (2)
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)